(By Balaseshan) Illumina Inc. (NASDAQ:ILMN), a developer and manufacturer of life science tools and integrated systems, said it has filed an additional patent infringement suit against Complete Genomics Inc. (NASDAQ:GNOM).
Illumina is seeking all available remedies, including injunctive relief. The new suit was filed in the U.S. District Court for the Southern District of California.
The new suit is based on Complete Genomics' infringement of U.S. Patent No. 8,192,930, entitled "Method for Sequencing a Polynucleotide Template." The suit targets Complete Genomics' Combinatorial Probe-Anchor Ligation (cPal) read technology.
Illumina previously sued Complete Genomics for infringement of U.S. Patent No. 6,306,597, in the U.S. District Court for the Northern District of California.
On February 8, the Court's Magistrate Judge Elizabeth Laporte issued a Claim Construction Order providing the court's interpretation of the disputed terms in the patent asserted by Illumina.
In its Order, the court adopted constructions favorable to Illumina for the key terms in dispute. Illumina believes that the court's interpretations affirm the breadth of the patent and Illumina's position that Complete Genomics infringes the patent.
Illumina owns or has exclusive licenses to more than 250 patents granted in the U.S. and many additional patents granted worldwide.
The company provides a line of genetic analysis solutions, with products and services that serve a range of interconnected markets, including sequencing, genotyping, gene expression, and molecular diagnostics. The company is organized in two business segments: Life Sciences and Diagnostics.
ILMN closed Friday's regular session up 1.40% at $39.81, while GNOM ended down 2.97% at $1.96.